1055 West Georgia Street
Vancouver, BC
Canada
https://www.mindbiotherapeutics.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein:
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Justin Adam Hanka | Co Founder, CEO & Director | S.O. | S.O. | 1974 |
Mr. John M. Dinan | Chief Financial Officer | S.O. | S.O. | 1958 |
Dr. Lahiru Russell Ph.D. | Chief Scientist | S.O. | S.O. | S.O. |
MindBio Therapeutics Corp., together with its subsidiaries, operates as a clinical stage drug development company in Canada, Australia, and New Zealand. The company engages in researching, developing, and testing microdosing of psychedelic substances as a potential treatment for the management of various mental health conditions, such as depression, anxiety, PTSD, panic disorder, chronic pain, and opiate addictions. Its LSD-microdosing is currently under Phase 2 clinical trials for the treatment of major depressive disorder and microdosing of LSD in late-stage cancer patients. The company was incorporated in 2021 and is headquartered in Vancouver, Canada.
L’ISS Governance QualityScore de MindBio Therapeutics Corp. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..